Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph Binkert, Keith Morrison, Walter Fischli, John Gatfield, Alexander Treiber, Thomas Weller, Martin H. Bolli, Christoph Boss, Stephan Buchmann, Bruno Capeleto, Patrick Hess, Changbin Qiu and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics December 2008, 327 (3) 736-745; DOI: https://doi.org/10.1124/jpet.108.142976
Marc Iglarz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Binkert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Morrison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Fischli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Gatfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Treiber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Weller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin H. Bolli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Boss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Buchmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Capeleto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hess
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changbin Qiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Clozel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N′-propylaminosulfonamide], is a new dual ETA/ETB endothelin (ET) receptor antagonist designed for tissue targeting. Selection of macitentan was based on inhibitory potency on both ET receptors and optimization of physicochemical properties to achieve high affinity for lipophilic milieu. In vivo, macitentan is metabolized into a major and pharmacologically active metabolite, ACT-132577. Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ETA and ETB receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory constants within the nanomolar range. In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ETA receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ETB receptors). In rats with pulmonary hypertension, macitentan prevented both the increase of pulmonary pressure and the right ventricle hypertrophy, and it markedly improved survival. In diabetic rats, chronic administration of macitentan decreased blood pressure and proteinuria and prevented end-organ damage (renal vascular hypertrophy and structural injury). In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats. This profile makes macitentan a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation.

Footnotes

  • This research is entirely supported by Actelion Pharmaceuticals Ltd., and all authors are employees of Actelion Pharmaceuticals Ltd.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.108.142976.

  • ABBREVIATIONS: ET, endothelin; ACT-064992, N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl]-N′-propylaminosulfonamide; FLIPR, fluorometric imaging plate reader; DOCA, deoxycorticosterone acetate; Veh, vehicle; MCT, monocrotaline; MPAP, mean pulmonary arterial pressure; RV, right ventricle; LV, left ventricle; S, septum; STZ, streptozotocin; VEGF, vascular endothelial growth factor; SB209670, (+)-(1S,2R,3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid; ACT-132577, [5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-sulfamide.

    • Received July 2, 2008.
    • Accepted September 8, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph Binkert, Keith Morrison, Walter Fischli, John Gatfield, Alexander Treiber, Thomas Weller, Martin H. Bolli, Christoph Boss, Stephan Buchmann, Bruno Capeleto, Patrick Hess, Changbin Qiu and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics December 1, 2008, 327 (3) 736-745; DOI: https://doi.org/10.1124/jpet.108.142976

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph Binkert, Keith Morrison, Walter Fischli, John Gatfield, Alexander Treiber, Thomas Weller, Martin H. Bolli, Christoph Boss, Stephan Buchmann, Bruno Capeleto, Patrick Hess, Changbin Qiu and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics December 1, 2008, 327 (3) 736-745; DOI: https://doi.org/10.1124/jpet.108.142976
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 4-Chloro ring-substituted synthetic cathinones
  • 14-3-3 Influences Nav1.5 Response to Anti-Arrhythmic Drugs
  • Inhaled Treprostinil Palmitil in the Sugen/Hypoxia Rat Model
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics